Veracyte Inc (NASDAQ:VCYT) Insider Sells $477,096.38 in Stock

Share on StockTwits

Veracyte Inc (NASDAQ:VCYT) insider John Walter Hanna, Jr. sold 18,593 shares of Veracyte stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $25.66, for a total transaction of $477,096.38. Following the sale, the insider now owns 84,085 shares in the company, valued at $2,157,621.10. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of NASDAQ VCYT opened at $26.05 on Friday. The company has a market capitalization of $1.26 billion, a P/E ratio of -42.02 and a beta of 1.07. Veracyte Inc has a 52-week low of $8.77 and a 52-week high of $31.18. The company’s 50 day moving average price is $25.69 and its 200-day moving average price is $25.32.

Veracyte (NASDAQ:VCYT) last issued its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.04. The firm had revenue of $30.14 million for the quarter, compared to the consensus estimate of $29.20 million. Veracyte had a negative net margin of 11.01% and a negative return on equity of 10.26%. On average, sell-side analysts expect that Veracyte Inc will post -0.23 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Gilder Gagnon Howe & Co. LLC acquired a new position in shares of Veracyte in the 1st quarter worth approximately $86,400,000. State Board of Administration of Florida Retirement System acquired a new position in shares of Veracyte in the 2nd quarter worth approximately $229,000. Russell Investments Group Ltd. lifted its position in shares of Veracyte by 24.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 245,093 shares of the biotechnology company’s stock valued at $6,966,000 after acquiring an additional 47,367 shares during the period. MUFG Securities EMEA plc acquired a new position in shares of Veracyte during the 2nd quarter valued at $2,222,000. Finally, Envestnet Asset Management Inc. acquired a new position in shares of Veracyte during the 2nd quarter valued at $638,000. Hedge funds and other institutional investors own 99.42% of the company’s stock.

Several research firms recently commented on VCYT. TheStreet upgraded shares of Veracyte from a “d” rating to a “c-” rating in a research report on Thursday, August 1st. ValuEngine downgraded shares of Veracyte from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 1st. BidaskClub downgraded shares of Veracyte from a “buy” rating to a “hold” rating in a research report on Thursday, September 5th. Needham & Company LLC set a $34.00 price target on shares of Veracyte and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Finally, Lake Street Capital began coverage on shares of Veracyte in a research report on Wednesday, July 31st. They issued a “buy” rating and a $35.00 price target on the stock. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $25.06.

About Veracyte

Veracyte, Inc operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis.

Further Reading: Quiet Period

Insider Buying and Selling by Quarter for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Country Club Trust Company n.a. Lowers Holdings in iShares MSCI Japan ETF
Country Club Trust Company n.a. Lowers Holdings in iShares MSCI Japan ETF
Country Club Trust Company n.a. Lowers Stake in SPDR Gold Shares
Country Club Trust Company n.a. Lowers Stake in SPDR Gold Shares
Enterprise Products Partners L.P.  Shares Purchased by Country Club Trust Company n.a.
Enterprise Products Partners L.P. Shares Purchased by Country Club Trust Company n.a.
Country Club Trust Company n.a. Has $346,000 Stock Position in Zoetis Inc
Country Club Trust Company n.a. Has $346,000 Stock Position in Zoetis Inc
Bailard Inc. Grows Position in iShares S&P 500 Value ETF
Bailard Inc. Grows Position in iShares S&P 500 Value ETF
Country Club Trust Company n.a. Cuts Stock Position in iShares Russell 2000 Value ETF
Country Club Trust Company n.a. Cuts Stock Position in iShares Russell 2000 Value ETF


© 2006-2019 Ticker Report